文献速递肿瘤 PET/CT骨显像与常规 SPECT

[18F]FDG PET/MRI联合胸部高分辨率CT在早期癌症检测中的应用:3020例无症状受试者的回顾性研究

[18F]FDG PET/MRI combined with chest HRCT in early cancer detection: a retrospective study of 3020 asymptomatic subjects.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-07-04

该回顾性研究纳入3020例接受全身[18F]FDG PET/MRI和胸部高分辨率CT的无症状受试者,随访2-4年。61例经病理确诊癌症,PET/MRI联合胸部CT正确检出59例,其中54例(91.5%)为0期或I期;联合检查对癌症的灵敏度为96.7%,单独PET/MRI为54.1%。作者认为PET/MRI对非肺癌早期检测有前景,但对早期肺癌似乎不足,胸部高分辨率CT可作为全身PET/MRI的补充。

要点

  • 3020例无症状受试者中,61例经病理确诊癌症,PET/MRI联合胸部高分辨率CT正确检出59例。
  • 联合检查灵敏度96.7%、特异度99.6%、阳性预测值83.1%、阴性预测值99.9%。
  • 单独PET/MRI灵敏度54.1%;对非肺癌灵敏度93.1%,对肺癌仅检出6例。

核心结论

  • [18F]FDG PET/MRI对非肺癌的早期检测有很大前景,但对早期肺癌的检测似乎不足。
  • 胸部高分辨率CT可与全身PET/MRI互补用于早期癌症检测。

研究设计与样本

  • 回顾性研究纳入3020例接受全身[18F]FDG PET/MRI和胸部高分辨率CT检查的无症状受试者。
  • 所有受试者接受2-4年随访以观察癌症发生。
  • 计算并分析[18F]FDG PET/MRI联合或不联合胸部高分辨率CT的癌症检出率、灵敏度、特异度、阳性预测值和阴性预测值。

主要发现

  • 61例经病理确诊癌症,PET/MRI联合胸部高分辨率CT正确检出59例。
  • 59例中54例(91.5%)为0期或I期(依据第8版TNM分期系统)。
  • 59例中33例(55.9%)由单独PET/MRI检出,包括27例非肺癌和6例肺癌。
  • PET/MRI联合胸部CT的癌症检出率、灵敏度、特异度、阳性预测值、阴性预测值分别为2.0%、96.7%、99.6%、83.1%、99.9%。
  • 单独PET/MRI的上述指标分别为1.1%、54.1%、99.6%、73.3%、99.1%;单独PET/MRI对非肺癌的上述指标分别为0.9%、93.1%、99.6%、69.2%、99.9%。

关键数值与推荐

  • 59例确诊癌症包括肺癌32例、乳腺癌9例、甲状腺癌6例、结肠癌5例、肾癌3例、前列腺癌1例、胃癌1例、子宫内膜癌1例、淋巴瘤1例。
  • 分期依据第8版TNM分期系统,54例(91.5%)为0期或I期。
  • PET/MRI联合胸部CT灵敏度96.7%、特异度99.6%、阳性预测值83.1%、阴性预测值99.9%。
  • 单独PET/MRI灵敏度54.1%、特异度99.6%、阳性预测值73.3%、阴性预测值99.1%。
  • 单独PET/MRI对非肺癌灵敏度93.1%、特异度99.6%、阳性预测值69.2%、阴性预测值99.9%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: PET/MRI has become an important medical imaging approach in clinical practice. In this study, we retrospectively investigated the detectability of fluorine-18 (18F)-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging ([18F]FDG PET/MRI) combined with chest computerized tomography (CT) for early cancer in a large cohort of asymptomatic subjects. METHODS: This study included a total of 3020 asymptomatic subjects who underwent whole-body [18F]FDG PET/MRI and chest HRCT examinations. All subjects received a 2-4-year follow-up for cancer development. Cancer detection rate, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the [18F]FDG PET/MRI with or without chest HRCT were calculated and analyzed. RESULTS: Sixty-one subjects were pathologically diagnosed with cancers, among which 59 were correctly detected by [18F]FDG PET/MRI combined with chest HRCT. Of the 59 patients (32 with lung cancer, 9 with breast cancer, 6 with thyroid cancer, 5 with colon cancer, 3 with renal cancer, 1 with prostate cancer, 1 with gastric cancer, 1 with endometrial cancer, and 1 with lymphoma), 54 (91.5%) were at stage 0 or stage I (according to the 8th edition of the tumor-node-metastasis [TNM] staging system), 33 (55.9%) were detected by PET/MRI alone (27 with non-lung cancers and 6 with lung cancer). Cancer detection rate, sensitivity, specificity, PPV, and NPV for PET/MRI combined with chest CT were 2.0%, 96.7%, 99.6%, 83.1%, and 99.9%, respectively. For PET/MRI alone, the metrics were 1.1%, 54.1%, 99.6%, 73.3%, and 99.1%, respectively, and for PET/MRI in non-lung cancers, the metrics were 0.9%, 93.1%, 99.6%, 69.2%, and 99.9%, respectively. CONCLUSIONS: [18F]FDG PET/MRI holds great promise for the early detection of non-lung cancers, while it seems insufficient for detecting early-stage lung cancers. Chest HRCT can be complementary to whole-body PET/MRI for early cancer detection. TRIAL REGISTRATION: ChiCTR2200060041. Registered 16 May 2022. Public site: https://www.chictr.org.cn/index.html.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Peng L, Liao Y, Zhou R, et al. [18F]FDG PET/MRI combined with chest HRCT in early cancer detection: a retrospective study of 3020 asymptomatic subjects. Eur J Nucl Med Mol Imaging. 2023. PMID: 37401938. doi:10.1007/s00259-023-06273-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。